BridgeBio Pharma (BridgeBio Pharma) Gross Profit : $6.86 Mil (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is BridgeBio Pharma Gross Profit?

BridgeBio Pharma's gross profit for the three months ended in Dec. 2023 was $1.15 Mil. BridgeBio Pharma's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $6.86 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. BridgeBio Pharma's gross profit for the three months ended in Dec. 2023 was $1.15 Mil. BridgeBio Pharma's Revenue for the three months ended in Dec. 2023 was $1.75 Mil. Therefore, BridgeBio Pharma's Gross Margin % for the quarter that ended in Dec. 2023 was 65.73%.

BridgeBio Pharma had a gross margin of 65.73% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 7 years, the highest Gross Margin % of BridgeBio Pharma was 95.58%. The lowest was 73.71%. And the median was 94.69%.

BridgeBio Pharma Gross Profit Historical Data

The historical data trend for BridgeBio Pharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BridgeBio Pharma Gross Profit Chart

BridgeBio Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Profit

Get a 7-Day Free Trial

38.06

8.25

66.60

74.21

6.86

BridgeBio Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Profit	Get a 7-Day Free Trial															1.22	1.18	1.04	3.49	1.15

Competitive Comparison of BridgeBio Pharma's Gross Profit

For the Biotechnology subindustry, BridgeBio Pharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Pharma's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Gross Profit falls into.

BridgeBio Pharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

BridgeBio Pharma's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	9.303	-	2.446
	=	6.86

BridgeBio Pharma's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )	=	Revenue	-	Cost of Goods Sold
	=	1.745	-	0.598
	=	1.15

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.86 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

BridgeBio Pharma's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	1.15	/	1.745
	=	65.73 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

BridgeBio Pharma (NAS:BBIO) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

BridgeBio Pharma had a gross margin of 65.73% for the quarter that ended in Dec. 2023 => Durable competitive advantage

BridgeBio Pharma Gross Profit Related Terms

Thank you for viewing the detailed overview of BridgeBio Pharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

BridgeBio Pharma (BridgeBio Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BridgeBio Pharma Inc (NAS:BBIO) » Definitions » Gross Profit

Comparable Companies

Traded in Other Exchanges

2CL:Germany

Address

3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304

Website

https://www.bridgebio.com

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy. The company focus on genetic diseases because they exist at the intersection of high unmet patient need and tractable biology.

Executives

Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Frank Mccormick	officer: Chairman of Oncology	C/O UCSF, 1450 3RD STREET, RM HD-371, SAN FRANCISCO CA 941439001
Randal W Scott	director	171 MAIN STREET #225, LOS ALTOS CA 94022
Neil Kumar	director, officer: See Remarks	C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Brian C Stephenson	officer: See Remarks	3160 PORTER DR, STE 250, PALO ALTO CA 94304
Viking Global Opportunities Parent Gp Llc	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Investors Lp	10 percent owner	600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Douglas A. Dachille	director	175 WATER STREET, NEW YORK NY 10038
Andrew Lo	director	C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
Ronald J Daniels	director	C/O MOORE CORPORATION LIMITED, ONE CANTERBURY GREEN, STAMFORD CT 06901
Fred Hassan	director	C/O CARET GROUP,, 1100 HOLLAND DR., BOCA RATON FL 33487
James C Momtazee	director	2884 SAND HILL ROAD, SUITE 100, MENLO PARK CA 94025
Brent L Saunders	director	2000 GALLOPING HILL ROAD, C/O SCHERING PLOUGH CORP, KENILWORTH NJ 07033
Andrea Ellis	director	C/O BRIDGEBIO PHARMA, INC., 421 KIPLING STREET, PALO ALTO CA 94301
Richard H Scheller	director, officer: See Remarks	C/O GENENTECH INC, 1 DNA WAY MS 49, SOUTH SAN FRANCISCO CA 94080-4990